Tenure track assistant/associate professor in the Department of Molecular & Integrative Physiology at the University of Michigan Medical School.

Proteomic analyses offer insights into how KRAS inhibitors affect oncogenic KRAS signaling.

Mutant RAS proteins are among the most prevalent drivers of human cancer, and the glycine to aspartic acid mutation at codon 12 (G12D) is the most common variant. Mutation-selective covalent inhibitor...

Costas Lyssiotis, Ph.D., co-director of the Rogel and Blondy Center for Pancreatic Cancer at the Rogel Cancer Center, was one of six researchers to receive inaugural grants from the Stephenson Global ...

Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by mutations in the Kirsten rat sarcoma virus (KRAS) oncogene. Due to the pivotal role…

Postdoctoral Scientist Position (f/m/d)

In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRASG12C inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively. However, rather than marking the end of a successful assault on the Mount Everest of cancer research, this landmark only revealed new challenges in RAS drug discovery. In this review, we highlight the progress on defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS therapies.

Immune surveillance is critical to prevent the development and progression of cutaneous squamous cell carcinoma (cSCC). Here, the authors show that epithelial-mesenchymal plasticity in cancer cells is...

Postdoctoral Scientist Position (f/m/d)

Identification of an LGR5 as a marker for a tripotent stem/progenitor cell of the human fetal pancreas. Organoids derived from single LGR5+ cells are capable of long-term expansion in vitro and genera...

Due to challenges in studying molecular interactions of CRBN, identification of CRBN based molecular glues has remained underexplored. Here, Bailey et al designed an easy-to-handle CRBN construct and ...

Else Kröner Medical Scientist Kollegs in Höhe von 3,3 Millionen Euro in den Bereichen der Immunologie, Genomik und Inflammation vergeben